EXACT Sciences (EXAS) PT Set at $100.00 by UBS Group

EXACT Sciences (NASDAQ:EXAS) has been given a $100.00 target price by stock analysts at UBS Group in a note issued to investors on Tuesday, www.tipranks.com reports. The brokerage currently has a “buy” rating on the medical research company’s stock. UBS Group’s target price indicates a potential upside of 40.75% from the company’s current price.

Several other equities analysts have also issued reports on the stock. Cowen lifted their target price on shares of EXACT Sciences from $65.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, September 5th. Bank of America lifted their target price on shares of EXACT Sciences from $68.00 to $92.00 and gave the stock a “buy” rating in a research report on Thursday, September 6th. BidaskClub downgraded shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research report on Friday, September 14th. Robert W. Baird lifted their target price on shares of EXACT Sciences from $74.00 to $85.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 11th. Finally, Canaccord Genuity lifted their target price on shares of EXACT Sciences from $72.00 to $87.00 and gave the stock a “buy” rating in a research report on Wednesday, September 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $84.08.

Shares of EXAS opened at $71.05 on Tuesday. The company has a quick ratio of 15.37, a current ratio of 15.79 and a debt-to-equity ratio of 0.87. EXACT Sciences has a one year low of $37.36 and a one year high of $81.22. The stock has a market capitalization of $7.91 billion, a price-to-earnings ratio of -71.77 and a beta of 0.98.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, October 30th. The medical research company reported ($0.37) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.05. EXACT Sciences had a negative net margin of 35.83% and a negative return on equity of 20.69%. The business had revenue of $118.29 million during the quarter, compared to analyst estimates of $109.33 million. During the same period last year, the business posted ($0.23) earnings per share. EXACT Sciences’s quarterly revenue was up 63.0% compared to the same quarter last year. Sell-side analysts predict that EXACT Sciences will post -1.44 EPS for the current fiscal year.

In other news, insider D Scott Coward sold 2,190 shares of EXACT Sciences stock in a transaction on Monday, October 1st. The shares were sold at an average price of $79.51, for a total transaction of $174,126.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael S. Wyzga sold 2,468 shares of EXACT Sciences stock in a transaction on Tuesday, August 28th. The stock was sold at an average price of $74.85, for a total transaction of $184,729.80. Following the transaction, the director now owns 9,112 shares in the company, valued at approximately $682,033.20. The disclosure for this sale can be found here. Insiders have sold a total of 62,658 shares of company stock worth $4,381,737 in the last quarter. Corporate insiders own 3.20% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Xact Kapitalforvaltning AB increased its holdings in shares of EXACT Sciences by 4.5% in the 3rd quarter. Xact Kapitalforvaltning AB now owns 18,725 shares of the medical research company’s stock worth $1,478,000 after buying an additional 800 shares during the last quarter. IFP Advisors Inc grew its holdings in EXACT Sciences by 49.4% during the 3rd quarter. IFP Advisors Inc now owns 6,192 shares of the medical research company’s stock valued at $489,000 after purchasing an additional 2,047 shares during the last quarter. First Mercantile Trust Co. grew its holdings in EXACT Sciences by 8.2% during the 2nd quarter. First Mercantile Trust Co. now owns 29,766 shares of the medical research company’s stock valued at $1,779,000 after purchasing an additional 2,261 shares during the last quarter. GSA Capital Partners LLP grew its holdings in EXACT Sciences by 30.2% during the 2nd quarter. GSA Capital Partners LLP now owns 10,683 shares of the medical research company’s stock valued at $639,000 after purchasing an additional 2,477 shares during the last quarter. Finally, Fulton Bank N.A. bought a new position in EXACT Sciences during the 3rd quarter valued at about $208,000. Institutional investors and hedge funds own 86.52% of the company’s stock.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

See Also: Hedge Funds – Risk or Reward?

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply